Markers of Bone Turnover for Monitoring Treatment of Osteoporosis with Antiresorptive Drugs
β Scribed by P. D. Delmas
- Publisher
- Springer-Verlag
- Year
- 2000
- Tongue
- English
- Weight
- 218 KB
- Volume
- 11
- Category
- Article
- ISSN
- 0937-941X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Denosumab, a fully human monoclonal antibody to RANKL, decreases bone remodeling, increases bone density, and reduces fracture risk. This study evaluates the time course and determinants of bone turnover marker (BTM) response during denosumab treatment, the percentage of denosumabβtreat
## Abstract Biochemical markers of bone turnover have been proposed to monitor the response to bisphosphonate therapy for osteoporosis, but this requires true betweenβperson differences in the response to therapy. Using mixed models we analyzed three annual measurements of two markers (bone alkalin